Figure S1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Martina S.J. McDermott; Neil A. O’Brien; Benjamin Hoffstrom; Ke Wei Gong; Ming Lu; Jun Zhang; Tong Luo; Min Liang; Weiping Jia; Jenny J. Hong; Kevin Chau; Simon Davenport; Bin Xie; Michael F. Press; Richard Panayiotou; Abram Handly‐Santana; Joan S. Brugge; Leonard Presta; John A. Glaspy; Dennis J. Slamon

doi:10.1158/1078-0432.27030364.v1

Key Points

CLDN6 transcript expression is characterized across normal human tissues, defining baseline levels for targeted therapies in solid tumors.
Analysis using the GTEx dataset profiles CLDN6 RNA transcript distribution, evaluating target presence across diverse non-cancerous tissues.
These baseline transcript levels may enable safe antibody-drug conjugate dosing, supporting preclinical CLDN6-23-ADC selectivity assessments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Transcriptomic analysis demonstrates CLDN6 expression patterns across normal tissue samples from the GTEx dataset, suggesting a low off-target profile.

Abstract

Supplemental Figure S1: Expression of CLDN6 by transcript in the GTEX dataset of normal tissue samples.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McDermott et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d07 https://doi.org/10.1158/1078-0432.27030364.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Figure S1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading